Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics, Inc. (APGE)
NASDAQ:APGE
RESEARCH TOOLSreports
Apogee Therapeutics, Inc. (APGE) Stock Price & Analysis
98 Followers
APGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.19 - $72.29
Previous Close$49.95
Volume341.12K
Average Volume (3M)465.50K
Market Cap
$2.92B
Enterprise Value$2.11B
Total Cash (Recent Filing)$816.20M
Total Debt (Recent Filing)$1.77M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 26, 2024EPS Estimate
-$0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,456,027
10 Day Avg. Volume538,630
30 Day Avg. Volume465,504
Standard Deviation0.34
R-Squared0.18
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)4.43
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-27.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-35.69
Forecast
1Y Price Target
$80.50Price Target Upside61.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Apogee Therapeutics, Inc. News
PremiumCompany Announcements
Apogee Therapeutics Welcomes Dr. Bollinger to Board
PremiumCompany Announcements
Apogee Therapeutics Starts Phase 2 Trial for Atopic Dermatitis DrugBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessSanofi's amlitelimab has met its primary endpoint in a Phase 2b study, demonstrating significant reductions in EASI score and durability of response.
Drug ApprovalThe CHMP has issued a positive opinion recommending the approval of Dupixent for COPD in the EU.
Market PotentialApogee's key assets, APG777 for atopic dermatitis and APG808 for asthma and COPD, are viewed as largely de-risked with potential for substantial market growth.
Bears Say
Market EntryThe biggest risk for Apogee is the timing of biosimilar Dupi’s entry into the market, which may impact pricing and reimbursement strategies.
Market EntryThe biggest risk for Apogee is the timing of biosimilar Dupi’s entry into the market, which may impact pricing and reimbursement.
RegulatoryThe FDA has requested additional subpopulation analyses for Dupixent in COPD which could potentially delay its sBLA approval.
---
Ownership Overview
12.61% Insiders
25.07% Mutual Funds
10.69% Other Institutional Investors
51.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APGE FAQ
What was Apogee Therapeutics, Inc.’s price range in the past 12 months?
Apogee Therapeutics, Inc. lowest stock price was $14.19 and its highest was $72.29 in the past 12 months.
What is Apogee Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Apogee Therapeutics, Inc.’s upcoming earnings report date?
Apogee Therapeutics, Inc.’s upcoming earnings report date is Aug 26, 2024 which is in 28 days.
How were Apogee Therapeutics, Inc.’s earnings last quarter?
Apogee Therapeutics, Inc. released its earnings results on May 13, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.587 by -$0.053.
Is Apogee Therapeutics, Inc. overvalued?
According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued.
Does Apogee Therapeutics, Inc. pay dividends?
Apogee Therapeutics, Inc. does not currently pay dividends.
What is Apogee Therapeutics, Inc.’s EPS estimate?
Apogee Therapeutics, Inc.’s EPS estimate is -$0.61.
How many shares outstanding does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has 44,969,383 shares outstanding.
What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?
Apogee Therapeutics, Inc. reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.587. Following the earnings report the stock price went down -0.921%.
Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?
Among the largest hedge funds holding Apogee Therapeutics, Inc.’s share is Perceptive Advisors LLC. It holds Apogee Therapeutics, Inc.’s shares valued at 179M.
---
Apogee Therapeutics, Inc. Stock Smart Score
Company Description
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
---
APGE Stock 12 Month Forecast
Average Price Target
$80.50
▲(61.16% Upside)
Technical Analysis
RAPT Therapeutics
―
Adverum Biotechnologies
―
Gritstone Oncology
―
Molecular Templates
―
Best Analysts Covering APGE
1 Year
1 Year Success Rate
3/4 ratings generated profit
1 Year Average Return
+53.15%
reiterated a buy rating 5 months ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +53.15% per trade.
---